Constellation Energy Corporation vs Cronos Group Inc — how do they compare? Constellation Energy Corporation trades at $279.76 (market cap $95.82B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Constellation Energy Corporation is far larger — about 86.3× Cronos Group Inc's market cap, and Constellation Energy Corporation pays a 0.63% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CEG | CRON | |
|---|---|---|
Market Cap | $95.82B | $1.11B |
Sector | Energy | Health |
52-Week High | $403.95 | $3.27 |
52-Week Low | $236.50 | $2.30 |
Enterprise Value | $119.82B | $310.67M |
Dividend Yield | 0.63% | — |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.
The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →